Improving RNA therapies delivered through intravenous infusion
Official title: Advanced tools for translation of intravenously-infused RNA LNP therapeutics to the clinic
Funded at Rejuvenation Technologies, INC. · NIH-11145225 · Data updated 2026-11-12
This study is looking at a new way to help people with age-related diseases, like liver and lung issues, by using special tiny particles to deliver a treatment that can help repair cells and improve their health without causing unwanted immune reactions.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rejuvenation Technologies, INC. NIH-funded |
| Lab location | 1 site (Mountain View, UNITED STATES) |
| Project start | August 1, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,065,587 |
| NIH project number | 5R44TR005328-02 |
| Project ID | NIH-11145225 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals suffering from age-related diseases such as liver fibrosis, lung fibrosis, or other conditions linked to telomere shortening.
✕Less likely to help
Patients with conditions unrelated to telomere shortening or those who do not require intravenous therapies may not benefit from this research.
What this research studies
This research focuses on enhancing the clinical application of RNA lipid nanoparticle (LNP) therapeutics that are infused intravenously. Unlike vaccines that provoke an immune response, these LNPs must be designed to avoid triggering such responses to ensure their effectiveness. The study will specifically investigate a telomere extension biologic aimed at treating age-related diseases by delivering modified TERT mRNA to restore telomere length, which is crucial for cellular regeneration. By using biodegradable lipid nanoparticles, the research aims to improve the safety and efficacy of these therapies for patients with conditions like liver and lung diseases.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance organ regeneration and combat age-related diseases.
How similar studies have gone: While there has been significant work on RNA LNP vaccines, the specific approach of using intravenously-infused LNPs for telomere extension is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Rejuvenation Technologies, INC.
Mountain View, United States Active
Researchers
- Principal investigator: Ramunas, John — Rejuvenation Technologies, INC.
- Study coordinator: Ramunas, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.